Fulvestrant

Various toxicities: 4 case reports

    This is a preview of subscription content, access via your institution.

    Notes

    1. 1.

      The patient demographics have been obtained though direct communication with the Author.

    Reference

    1. Zhao Y, et al. Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real-world study for patients with hormone receptor-positive and HER2-negative advanced breast cancer. Cancer Medicine 9: 8821-8831, No. 23, Dec 2020. Available from: URL: https://doi.org/10.1002/cam4.3491

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Fulvestrant. Reactions Weekly 1840, 197 (2021). https://doi.org/10.1007/s40278-021-90340-2

    Download citation